BACKGROUND. Hepatoblastoma is the most common primary malignant liver tumor affecting infants and young children. Recent clinical experience with advanced hepatoblastoma shows that a reliable in vivo model to study the tumor's response to drugs is needed urgently. ## METHODS. Hepatoblastoma cell s
Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma
✍ Scribed by D.von Schweinitz; D.J Byrd; H Hecker; P Weinel; U Bode; D Bürger; R Erttmann; D Harms; H Mildenberger
- Book ID
- 117663840
- Publisher
- Elsevier Science
- Year
- 1997
- Tongue
- English
- Weight
- 880 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Sixteen children, aged 16 days to 13 years with hepatoblastoma (HB) (13 patients) or hepatocellular carcinoma (HCC) (3 patients), were given a total of 89 courses of cisplatin and doxorubicin (PLADO) as IV continuous infusion. All tumors were confined to the liver except for 1 hepatoblastoma patient
Nine of 11 patients with hepatoblastoma CR of pulmonary lesions. The average interval treated with cisplatin (DDP) based chemo-of disease control following DDP was three therapy had a complete (CR) or partial (PR) times that of Adriamycin (ADR). DDP is an remission. Five of these patients had measur